Dr. Nathan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
no office
Moorestown, NJ 08057- Is this information wrong?
Summary
- Dr. Faith Nathan is an oncologist in Moorestown, NJ. She received her medical degree from Rutgers New Jersey Medical School and has been in practice 30 years. She specializes in genitourinary oncology, hematologic oncology, and thoracic cancer and is experienced in immunotherapy, urologic oncology, thoracic oncology, clinical trials as topic, and lung neoplasms. She has more than 40 publications and over 500 citings. She retired in July 2023.
Education & Training
- Drexel University College of Medicine/Hahnemann University HospitalFellowship, Hematology and Medical Oncology, 1989 - 1992
- Cooper Medical School of Rowan University/Cooper University HospitalResidency, Internal Medicine, 1987 - 1989
- Rutgers New Jersey Medical SchoolClass of 1986
Certifications & Licensure
- NJ State Medical License 1987 - 2023
- PA State Medical License 1988 - 2006
- American Board of Internal Medicine Internal Medicine
Clinical Trials
- A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel Start of enrollment: 2006 Mar 01
Publications & Presentations
PubMed
- 96 citationsProtracted survival after resection of metastatic uveal melanoma.Takekazu Aoyama M.D., Michael J. Mastrangelo, David Berd, Faith E. Nathan, Carol L. Shields
Cancer. 2000-10-01 - 2113 citationsNivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational BurdenMatthew D. Hellmann, Tudor-Eliade Ciuleanu, Adam Pluzanski, Jong-Seok Lee, Gregory A. Otterson
The New England Journal of Medicine. 2018-04-16 - 26 citationsFirst-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1.Martin Reck, Tudor Ciuleanu, Jong Seok Lee, Michael Schenker, Clarisse Audigier-Valette
Journal of Thoracic Oncology. 2021-04-01
Journal Articles
- Pain in castration-resistant prostate cancer with bone metastases: a qualitative studyGater A, Abetz-Webb L, Battersby C, Parasuraman B, McIntosh S, Nathan F, Piault EC, Health & Quality of Life Outcomes, 2011
- Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care populationEngel-Nitz NM, Alemayehu B, Parry D, Nathan F, Cancer management and research, 2011
- A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advan...Chouaid C, Nathan F, Pemberton K, Morris T, Cancer Chemother Pharmacol, 2011
- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: